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ABSTRACT 
During intestinal inflammation, the disruption of the intestinal mucosa barrier 
enabled the luminal microbiota to come into direct contact with the underlying 
immune cells, which results in inflammatory response. The recognition of the luminal 
microbiota by the Toll-like receptors (TLRs) activates downstream signalling 
pathways such as the mitogen-activated protein kinase (MAPK). The MAPK pathway 
is essential in regulating immune response and its negative regulation is controlled by 
MAPK phosphatases (MKPs). MKP-3, also known as DUSP6, is a MAPK 
phosphatase with high specificity towards ERK, which is known to regulate cell 
proliferation. The role of MKPs in immune cells has been widely studied but the role 
of MKPs in the intestinal epithelial cells (IEC) during intestinal inflammation has yet 
to be explored. In this study, we utilised CMT93 cells overexpressing MKP-3 and 
dextran sodium sulphate (DSS)-induced colitis model in mice deficient in MKP-3 to 
investigate the role of MKP-3 in intestinal inflammation. The results showed that 
overexpression of MKP-3 downregulated the phosphorylation of all three major 
groups of MAPKs (ERK, JNK and p38) and pro-inflammatory gene expression upon 
DSS and LPS stimulation. In addition, the overexpression of MKP-3 retarded cell 
proliferation and wound healing ability of CMT93 cells. MKP-3-/- mice subjected to 7 
days of DSS treatment developed less severe colitis compared to the wildtype mice. 
mRNA and protein analysis showed that the expression of pro-inflammatory genes 
was reduced and the phosphorylation of ERK was increased in the colon of MKP-3-/- 
mice. The expression of proliferation genes and Krüppel-like transcription factor 5 
(KLF5) protein was also elevated in the colon of MKP-3-/- mice. In addition, Ki67 
staining showed increased IEC proliferation in the colon of MKP-3-/- mice. These 
results suggested the role of MKP-3 in IEC during intestinal inflammation by 
affecting inflammatory gene expression, IEC proliferation and restitution. 
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1. Introduction 
1.1. Inflammatory Bowel Diseases (IBD) 
Inflammatory bowel diseases (IBD) is a term used to describe the chronic 
relapsing inflammatory condition in the gastrointestinal tract. The two major 
conditions of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). UC is 
characterised by continuous inflammation and superficial ulceration in the mucosa 
and submucosa of the colon accompanied by crypt abscesses. The primary infiltrates 
in UC are neutrophils and lymphocytes, which are densely present in the lamina 
propria. In contrast of UC which is only limited to the colon, the inflammation in CD 
can be anywhere along the gastrointestinal tract. The involvement of various parts of 
the gastrointestinal tract in CD causes a broader range of clinical manifestation such 
as nutritional deficiency. In addition, the ulceration in CD is deeper into the intestinal 
wall and the inflammation is usually segmented, whereby alteration between normal 
and inflamed region is commonly found. The primary infiltrates in CD are 
macrophages and lymphocytes which often form non-caseating granulomas 1–4. 
IBD is mostly prevalent in North America, Northern Europe and the UK 
although the rate of incidence is rising in Southern Europe, Asia and most developing 
countries 5. Despite the understanding of the characteristics of IBD, the exact causes 
of the disease remain elusive. There are several multiple causes of IBD which are  
known to contribute towards the pathogenesis of the disease. These key contributing 
factors are genetics predisposition, environmental factors and factors affected by 
lifestyle such as host/mucosa immune response, mucosa epithelial barrier and gut 
microbiota 6. 
  2 
1.1.1. Causes and Pathogenesis of IBD 
Higher prevalence of IBD in certain ethnic groups such as Jewish becomes a 
supporting evidence that genetic makeup contributes to the development of the 
disease. In addition, family history of IBD is a strong contributing risk factor towards 
the development of the disease in an individual 5. Genome wide association studies 
(GWAS) have identified several susceptibility genes across several regions in the 
chromosome. These studies revealed several pathways that are affected by the 
identified genes, which may play important roles in the pathogenesis of IBD. These 
pathways involve intestinal epithelia integrity, innate and adaptive immune responses, 
autophagy, endoplasmic reticulum (ER) stress and numerous other regulatory 
pathways that are yet to be elucidated 7,8. These pathways may also affect each other, 
which further shows IBD as a polygenic disease 9. 
It is also interesting to note that despite being born with the predisposed genetic 
background, most individuals do not develop IBD symptoms until later in life. This 
shows that besides genetic predisposition, environmental and lifestyle factors play a 
role in the development of IBD in individuals. Smoking is one of the lifestyle factors 
that exacerbates CD but on the contrary protects against UC 10. Several hypotheses 
have also suggested exposure to environmental antigens and access to hygiene and 
sanitation as factors that contribute to the development of IBD. Growing up in highly 
sanitised environment may impair the development of the immune system by 
restricting antigen exposure, which in turn causes the immune system to have 
exaggerated response to the antigen later in life 5. 
As with the uncertain cause of the disease, the pathogenesis of IBD is still 
unclear. The recent understanding of the disease speculates that IBD is a result of the 
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shift in intestinal microbial content, breakdown of the protective barrier of the 
intestinal epithelia and/or a dysregulation in the immune system 4,11. The composition 
of the intestinal microflora has been associated with human IBD. For example, 
adherent-invasive E. coli was found in colonic lesions from CD patients and has been 
associated with ileal mucosa of CD patients 12,13. The presence of the bacteria in early 
recurrent lesions indicates that it plays a role in the initiation of inflammation. In 
addition, its ability to survive and replicate within macrophages has been thought to 
contribute to its ability to spread within the intestinal mucosa and trigger chronic 
inflammatory response 13.  
Besides the intestinal microflora, the loss of intestinal epithelial integrity and 
function is an early event in IBD pathogenesis 11. Increased and sustained intestinal 
epithelial ER stress caused by unfolded protein response (UPR) can trigger apoptosis. 
UPR is a cytoprotective mechanism to prevent the accumulation of misfolded protein 
in the cell. Accumulation of misfolded protein causes sustained ER stress, which in 
turn result in apoptosis of the intestinal epithelial cells (IEC). Studies in mice with 
MUC2 missense mutation showed increased ER stress in the IEC, which causes 
susceptibility to colitis 14. Besides ER stress, other factors such as dysregulation in 
transcription factors involved in IEC regeneration and breakdown in tight junction 
proteins such as ZO-1 and ZO-2 have also been linked to the pathogenesis of IBD 4. 
Similar to many other autoimmune diseases, the pathogenesis of IBD involves 
the dysregulation of T cell responses. Earlier findings have suggested CD and UC as a 
result of T helper 1 (Th1) and T helper 2 (Th2) response, respectively 15. However this 
paradigm remains controversial as other observations showed mixed cytokine profiles 
in ex vivo cultures from IBD patients 16,17. In addition, increased level of IL-17A in 
the intestinal mucosa of IBD patients has also indicated the involvement of T helper 
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17 (Th17) responses in the disease 18. Previous studies have shown plasticity in the 
late stage development of Th17 and regulatory T (Treg) cells, and that each T cell 
requires TGF-# for differentiation 19. As TGF-# is abundant in the intestines, this 
finding may indicate the involvement of the balance between these two T cell 
responses in IBD. The presence of inflammatory cytokines, such as IL-6 or IL-21, 
promotes the development of Th17 in the intestines, which otherwise would 
predominate towards Treg differentiation to maintain the state of tolerance 4,20.  
In summary, the pathogenesis of IBD involves a complex interplay of these 
three factors, and it is most likely that the occurrence of one would trigger the others. 
An illustrated summary of the pathogenesis of IBD is shown in Figure 1.1. 
 
Figure 1.1 Schematic diagram illustrating the pathogenesis of UC 21. (A) The 
pathogenesis of UC could initiate from the disruption in intestinal epithelial barrier. 
(B) This causes the luminal microbiota to come in contact with underlying immune 
cells in the lamina propria. Upon recognising the antigenic luminal microbiota, 
antigen presenting cells (APCs) such as macrophages and dendritic cells become 
activated and secrete pro-inflammatory cytokines (innate immunity). (C) The antigens 
are presented by the APCs to the naïve T cells, which results in T cell responses 
(adaptive immunity).  
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1.1.2. Dextran Sulphate Sodium (DSS)-induced Murine Model of Colitis 
There are numerous animal models of colitis that have been used to mimic IBD 
in humans. In this study, the DSS-induced murine model of colitis was employed. 
DSS is a sulphated polymer of glucose with varying molecular weight depending on 
the length of the polymer chain. In this study, the mice were administered DSS with 
molecular weight of approximately 36-50 kDa, which is known to affect the distal 
colon 22. Therefore, the phenotypic change of the mice administered with DSS closely 
mimics the clinical features of UC in humans. The mechanism by which DSS causes 
intestinal inflammation has not been precisely understood but the chemical is believed 
to affect the intestinal epithelial barrier function. A study showed that DSS penetrated 
and caused disruption to the intestinal mucus layer. Damage in the mucus layer 
allowed the luminal bacteria to come into contact with the intestinal epithelia, which 
then triggered an immune response 23. Another study suggested that the sulphate 
group in DSS form electrostatic interaction with medium- or long-chained fatty acid 
in the intestines, which then enables the complex to enter the epithelial cells and 
trigger pro-inflammatory response in those cells 24.   
1.2. The Role of Immune Response in Intestinal Inflammation 
The gastrointestinal tract contains more than 500 species of microbiota which 
are constantly in contact with the luminal wall 5. In normal individuals, the intestinal 
epithelia layer provides a physical barrier that separates the microbiota from the 
immune cells in the lamina propria. In addition, the immune system is anergic 
towards this population of commensal microorganisms. However during intestinal 
inflammation, the barrier of epithelia layer is disrupted and the immune system form 
an exaggerated response towards these microorganisms, which causes chronic 
inflammation 25.  
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Underneath the epithelia layer of the intestines lies the lamina propria where 
resident innate immune cells such as dendritic cells and macrophages reside. These 
innate immune cells constantly sample the antigens from the microbiota in the 
intestinal lumen and maintain immune tolerance towards them. Resident macrophages 
in the lamina propria are known to produce IL-10, which prevents inflammation by 
inducing and sustaining expression of Foxp3 transcription factor in regulatory T cells 
(Treg) 26. In addition, it has also been suggested that IL-10 suppresses pro-
inflammatory response to pathogen-associated molecular pattern (PAMP) in 
macrophages through suppression of IL-12p40 expression 27. Aside from producing 
IL-10, these macrophages are also hyporesponsive due to reduced expression of Toll-
like receptor (TLR) and other surface receptors that are required for macrophage 
activation 28. Meanwhile, CD103+ dendritic cells in the intestines are also capable of 
inducing Foxp3 expression in Treg cells by producing retinoic acid and TGF-# in order 
to sustain the state of tolerance 29.  
However when intestinal inflammation occurs, the epithelia mucosa barrier is 
disrupted and the innate immune cells mount inflammatory response towards the gut 
microbiota. Once the epithelia and immune cells are exposed to the gut microbiota, 
they are recognised by the TLRs. This results in the recruitment of intracellular 
adaptor molecules such as Myeloid differentiation primary response 88 (MyD88), 
Toll-interleukin 1 receptor domain containing adaptor protein (TIRAP), 
Toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-! (TRIF) 
and Toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-!-
related adaptor molecule (TRAM), which activate downstream signalling pathways. 
The TRIF-dependent pathway of the TLR signalling leads to the activation of Nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-"B) and Interferon 
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regulatory transcription factor 3 (IRF3) and results in the induction of type I 
interferon and inflammatory cytokines. Meanwhile, the MyD88-dependent pathway 
leads to the activation of NF-"B and MAPK and results in the induction of 
inflammatory cytokines 30.  
In the intestines, one of the early responses in intestinal inflammatory 
conditions such as IBD is mounted by neutrophils. The infiltrating neutrophil 
produces antimicrobial peptides and reactive oxygen intermediates which causes 
tissue damage. Besides causing tissue damage, the neutrophils also recruit other white 
blood cells such as macrophages by producing TNF-$, IL-1#, IL-6 and IL-8 31. The 
accumulation of macrophages at the inflamed site results in further tissue damage via 
secretion of TNF-$, IL-1# and proteases 32. In addition, activated macrophages 
produce more cytokines, which drives T cell polarization and differentiation into T 
helper cells. In IBD patients, this inflammation does not resolve and results in 
vascular leakage and further exposure of the luminal microbiota to the immune cells 
lying underneath the epithelium, thus causing the chronic inflammation in the 
intestine. 
1.3. The Role of Intestinal Epithelium in Intestinal Inflammation 
The intestinal epithelia layer provides a physical and physiological barrier 
between the luminal microbiota and the immune cells in the lamina propria. The 
intestinal epithelia layer is covered by a thick mucus layer consisting of mucin 
glycoprotein, phospholipids and antimicrobial peptides, which are mostly secreted by 
cells in the epithelia. Besides preventing direct contact between the luminal 
microbiota with the epithelial cells, the mucus layer also hydrates the epithelia layer 
and provides lubrication for the smooth flowing of the luminal content, as well as 
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homes secreted IgA which binds to luminal bacteria that are trapped in the mucus 
layer 33. When the mucus layer is disrupted, the epithelial cells are exposed to the 
luminal microbiota. Upon recognizing the antigens on the luminal bacteria, the 
epithelia cells produce pro-inflammatory cytokines and chemokines in defensive 
response to the bacteria. Recognition of the bacterial antigens by epithelia cells, 
likewise in innate immune cells like macrophages and dendritic cells, is also mediated 
by the pattern recognition receptors (PRR) such as TLRs 34. Secretion of pro-
inflammatory cytokines and chemokines by the intestinal epithelia results in the 
recruitment of immune cells to the inflammation site and epithelial damage.  
Upon injury to the epithelia layer, there are several mechanisms of which the 
epithelia layer restores its barrier integrity. After an injury, the adjacent epithelia cells 
migrate to the site of injury to re-establish the barrier continuity in a process called 
restitution. This mechanism does not require cell proliferation and occurs within 
minutes to hours after epithelial injury. During this process, the nearby epithelia cells 
dedifferentiate into pseudopodia-like structure and migrate to the wound site. Upon 
reaching the wound site, the cells would then reorganize their cytoskeleton and 
redifferentiate to complete the wound closure 35–37. There are numerous regulatory 
factors that affect epithelia restitution in the intestine: growth factors, cytokines, 
neuropeptides, polyamines, luminal peptides and probiotics 37. These factors are 
produced and secreted by not only the epithelia cells but also the underlying immune 
cells, as well as contribution from the luminal content 36.  
Another mechanism that accompanies epithelial restitution is cell proliferation 
and differentiation. In order to replenish the decreased epithelial cell pool due to 
injury, the epithelia layer needs to regenerate more cells. Nevertheless, apart from 
intestinal epithelia injury, cell proliferation and differentiation by itself is a part of 
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normal epithelia physiology. The cells on the epithelia layer are constantly being shed 
off into the lumen and replaced with new cells as a part of normal epithelia turnover. 
In the colon, the cellular proliferation occurs at the base of the crypt. As the daughter 
cells migrate to the surface of the epithelia, they differentiate into epithelia cells 38. In 
the event of epithelia injury where more cells are shed off than usual, cell 
proliferation and differentiation becomes a very important process to re-establish the 
barrier integrity. A schematic diagram illustrating intestinal epithelial wound healing 
process is shown in Figure 1.2. 
 
Figure 1.2 A schematic diagram showing wound healing process in the intestines. 
The lack of intestinal epithelia integrity has been implicated in intestinal 
inflammation. Numerous studies using animal models of gene knockouts have shown 
the importance of epithelial integrity in colitis whereby absence of genes that affect 
the regulation of wound healing, proliferation, differentiation and apoptosis in 
intestinal epithelia have been shown to play crucial role in the phenotypic outcome in 
the animals 39–41. In IBD patients, lack of intestinal epithelia integrity and increase in 
intestinal barrier permeability has been thought to be the primary cause, if not the 
exacerbating factor, of the disease 33. Since the epithelial barrier separates the luminal 
microbiota from the immune cells, the breach of this barrier would expose the luminal 
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bacteria to the immune cells and cause or even exacerbate the already existing 
inflammation.  
The epithelial barrier is important in maintaining the intestinal homeostasis by 
constantly undergoing repair through cell proliferation and restitution to replace aged 
or damaged epithelia cells. Upon injury, the epithelia layer senses the invasion of 
intestinal bacteria through the TLRs, which culminates in the activation of the NF-"B 
and MAPK pathways. While the role NF-"B and its regulation have been 
characterised in the gut 39,42, the role of MAPK phosphatases, the major negative 
regulator or MAPKs, and its regulation towards MAPKs in the gut have not been fully 
understood. 
1.4. Mitogen-Activated Protein Kinases (MAPKs) 
The MAPK signalling pathway is an evolutionarily conserved pathway that 
conveys extracellular stimuli from receptors on the cell surface to the target genes in 
the cell. This pathway regulates a wide range of cellular processes including cell 
proliferation, differentiation, motility, survival, apoptosis, metabolism and 
inflammation 43–45. The activation of MAPKs occurs through phosphorylation on their 
threonine and tyrosine residues in a three-tiered cascade of kinases. The MAPKs are 
activated by MAPK kinase (MKKs), which in turn are activated by MAPK kinase 
kinases (MKKKs) 46,47. Once activated, MAPKs will then act on their substrate (eg. 
protein kinases, cytoskeletal proteins, phospholipases or transcription factors) to exert 
their effects on cellular processes 47.  
There are three major groups of MAPKs in mammals: extracellular signal-
regulated protein kinases (ERK), c-Jun NH2-terminal kinases (JNK) and p38 proteins. 
They each differ in their tripeptide motif (Thr-Glu-Tyr for ERK, Thr-Pro-Tyr for JNK 
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and Thr-Gly-Tyr for p38), which allows specific activation by their upstream MKKs 
46,47. The ERK pathway is activated from Raf serine/threonine kinases at the MKKK 
level. Raf activates MKK1 and MKK2 which in turn activates ERK1 and ERK2 48. 
Meanwhile, the JNK pathway was found to be activated from several upstream 
kinases such as transforming growth factor-# activated kinase 1 (TAK1), MEKK3, 
Tumour Progression Locus 2 (TPL2) and Mixed Lineage Kinase 3 (MLK3). 
Activated forms of these kinases in turn activates MKK4 and MKK7 which then 
activates JNK 49. In the p38 pathway, upstream kinases at the MKKK level such as 
Apoptosis signal-regulating kinase 1 (ASK1), TAK1, Dual Leucine Zipper-bearing 
Kinase (DLK) and MEKK4 have been identified to regulate p38 activation through 
MKK3, MKK4 and MKK6 50. Both JNK and p38 pathway share several upstream 
kinases (eg. MKK4), and are known to be activated simultaneously under certain 
stimuli 45. The JNK and p38 pathways are normally more responsive to environmental 
stress, while the ERK pathway is preferentially activated by growth factors. The 
different levels of protein kinases that activate the MAPKs are illustrated in Figure 
1.3.  
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Figure 1.3 A simplified schematic diagram of MAPK signalling pathway 45,48–50. 
1.4.1. The Role of MAPKs in the Immune Response 
TLRs are important PRRs found on both cell surface and in the cytoplasm. 
These receptors recognize PAMPs present in pathogens and help to mount immune 
response against invading pathogens. The binding of TLR ligands results in activation 
of several signalling cascades to regulate the expression of numerous genes which 
would help to fight against pathogens and to further recruit more immune cells 51. One 
of the signalling cascades activated downstream of the TLRs is the MAPK pathway.  
The MAPK pathway is an important signalling cascade in the mediation of 
innate immune response. In macrophages, ERK is essential for the production of 
cytokines including TNF-$, IL-1# and IL-10 upon TLR stimulation. JNK activation 
is important for the macrophage M1 polarization which have enhanced production of 
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inflammatory cytokines such as TNF-$, IL6 and IL-12 51. Meanwhile, p38 activation 
by several TLRs stimulation results in the regulation of several pro-inflammatory 
factors such as TNF-$, IL-6, Cox2 and iNOS 52. Downstream p38 targets such as 
MSK1 and MSK2 also play a role in pro-inflammatory negative feedback loop in 
macrophages by inducing the expression of anti-inflammatory cytokine IL-10 and 
MAPK phosphatase-1 which deactivates both p38 and JNK 53. 
MAPKs have also been shown to play an important role in adaptive immunity. 
The Ras/ERK pathway is activated downstream of T cell receptor (TCR) engagement 
by antigen presenting cells (APC) and is essential in thymocyte development, T cell 
proliferation and IL-2 production 48. ERK has also been shown to be important in Th2 
cells differentiation. Inhibition of ERK in naïve T cells negatively affects the early IL-
4 expression upon TCR stimulation and the subsequent Th2 differentiation 54. JNK 
activation can be observed soon after T cell activation, indicating its role in this 
process. CD4+ T cells from JNK2-/- mice had impaired Th1 differentiation and IFN-! 
production, while CD4+ T cells from JNK1-/- mice had enhanced Th2 differentiation. 
This suggests that JNK2 may be important for Th1 differentiation while JNK1 is a 
negative regulator for Th2 differentiation. In T cell effector function, JNK activation 
was observed after restimulation of Th1 cells, but the activation was minimal in 
restimulated Th2 cells 52. The activation of p38 has also been shown to be important 
for T cell differentiation. p38 activation plays a role in Th1, but not Th2,  
differentiation and cytokine production. This was shown where the inhibition of p38 
resulted in the inhibition of IFN-! production by Th1 cells, but had no effect on IL-4 
production by Th2 cells 46. It was also shown in vitro that suppression of p38 in 
induced Treg cells results in enhanced proliferation of the cells and possibly loss of 
anti-inflammatory action of the cells 52. 
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1.4.2. The Role of MAPKs in Cell Proliferation and Survival 
As discussed in section 1.3., cell proliferation and restitution are important in 
maintaining intestinal epithelial barrier. One of the mechanisms that regulate these 
processes is the activation of ERK. The ERK pathway is one of the important 
signalling pathways in cell proliferation 55. Dysregulation in the ERK pathway has 
been implicated in human colorectal cancer, which shows that this pathway plays an 
important role in regulating intestinal cell proliferation and homeostasis 56. There are 
several extracellular growth factors that exert their effects through the ERK pathway. 
One of such growth factor stimuli is the epidermal growth factor (EGF). Binding of 
EGF to its receptor on the cell surface causes auto-phosphorylation of the cytoplasmic 
tail of the receptor. This phosphorylation allows recruitment of an adaptor protein, 
growth factor receptor-bound protein 2 (Grb-2), which further recruits son of 
sevenless (SOS). This complex then activates Ras by removing guanosine 
diphosphate (GDP) and allowing loading of guanosine triphosphote (GTP) to Ras. 
Activated Ras ultimately lead to the activation of ERK through the Raf/MKK/ERK 
kinase cascade 57. Upon phosphorylation, ERK translocates from the cytoplasm to the 
nucleus to target gene expression. The activation of ERK has been shown to induce 
the expression of cyclin D1, which promotes cell division 58. In addition, the 
Ras/Raf/MKK/ERK pathway also regulates numerous molecules that regulate cell 
cycle progression such as cyclin-dependent kinase (CDK) inhibitors, p16Ink4a, p15Ink4b 
and p21Cip1 56,59. In cell survival, ERK was shown to be anti-apoptotic by 
phosphorylating pro-apoptotic Bim and subjecting it to ubiquitination 59.  
The role of JNK in cell proliferation differs between JNK1 and JNK2 in 
regulating JUN, a positive regulator of cell cycle progression. While JNK1 
phosphorylates and stabilizes JUN, JNK2 targets JUN for degradation 45. Meanwhile, 
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in cell survival, JNK has been shown to be pro-apoptotic. JNK is a mediator of TNF-
$ dependent apoptosis through the caspase-8 activation pathway. JNK is also 
involved in the expression of several pro-apoptotic molecules such as TNF-$, Fas 
ligand (FasL), Bcl-2-associated X protein (BAX), Bcl-2-associated death promoter 
(BAD) and 14-3-3 protein 45,60. 
p38 negatively regulates cell proliferation through modulation of several factors 
in cell cycle progression. During G1/S and G2/M transition, p38 has been shown to 
upregulate CDK inhibitors and downregulate cyclins 45. In primary fibroblasts, p38 
can prevent tumorigenesis by inducing cell senescence through phosphorylating p53 
and upregulation of p16, a CDK inhibitor 45,61. As a responder to several external 
stress stimuli, p38 pathway is also involved in apoptosis. In immortalized cell lines, 
p38 has been shown to induce apoptosis in response to reactive oxygen species (ROS) 
production driven by oncogenes. p38 can also promote cell survival by induction of 
cell differentiation and production of anti-apoptotic inflammatory cytokine IL-6. In 
addition, p38 can trigger cell cycle arrest and DNA repair during the G2/M 
checkpoint which contributes to resistance towards apoptotic drugs in cancer cells 45. 
Although the activation of MAPK is important in regulating cell proliferation 
and growth, prolonged activation of MAPK can lead to disease phenotypes such as 
cancer. Activating Ras mutations are most commonly found in human carcinomas, 
melanomas and myeloid malignancies 62,63. Being a downstream effector of Ras, 
constantly activated ERK can result in uncontrolled cell proliferation and growth, 
which leads to tumour development. Therefore in order to regulate ERK signalling, a 
negative feedback mechanism is needed. Such negative regulation is provided by 
MAPK phosphatases. 
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1.5. MAPK Phosphatases (MKPs) 
MKPs, also known as dual specificity phosphatases (DUSP), are protein 
phosphatases that dephosphorylate activated MAPKs at their phosphothreonine and 
phosphotyrosine residues. Due to their capacity as negative regulators of MAPKs, 
MKPs are important molecules in modulating MAPK-mediated cellular responses 
towards external stimuli 44. To date there have been 10 MKPs identified so far and 
each MKP has been shown to have a specific substrate preference towards different 
members of MAPKs, depending on the cell types 64.  
 MKPs have different pattern of expression and subcellular localisations in the 
cell. MKP-1, DUSP2, MKP-2 and DUSP5 are localized in the nucleus and their 
expression is rapidly inducible by stress stimuli 64. Being products of immediate-early 
genes, these MKPs function as a negative feedback control for MAPK activation. 
These MKPs are also important in rapidly modulating the magnitude and duration of 
the MAPK activation, which could be prolonged and potentially harmful to the cell if 
uncontrolled. Meanwhile, MKP-3, MKP-4 and MKP-X are cytoplasmic MKPs, while 
DUSP8, MKP-5 and MKP-7 are both nuclear and cytoplasmic MKPs. These latter 
MKPs are not products of immediate-early genes and are normally induced at a much 
slower rate 44,64. Besides deactivating MAPKs, MKPs also plays a role in anchoring 
their specific MAPK substrate to its subcellular localisation, preventing interaction 
with its downstream targets 44. A summary of different MKPs is provided in Table 
1.1. 
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Table 1.1 A summary of different types of MKPs, their specificity and cellular 
localisation 44.  
Name Species orthologues Specificity Localisation 
MKP-1 DUSP1, CL100, HVH1, 
3CH134, ERP 
p38 ~ JNK >> ERK Nuclear 
MKP-2 DUSP4, HVH2, TYP1 ERK ~ JNK >> p38 Nuclear 
MKP-3 DUSP6, PYST1, RVH6 ERK >> JNK ~ p38 Cytosolic 
MKP-4 DUSP9, PYST3 ERK > p38 > JNK Nuclear and 
cytosolic 
MKP-5 DUSP10 p38 ~ JNK >> ERK Nuclear and 
cytosolic 
MKP-7 MKPM, DUSP16 JNK ~ p38 >> ERK Cytosolic 
MKP-X DUSP7, B59, PYST2 ERK >> JNK ~ p38 Cytosolic 
DUSP2 PAC1 ERK ~ p38 >> JNK Nuclear 
HVH3 DUSP5, B23 ERK Nuclear 
HVH5 DUSP8, M3/M6 JNK ~ p38 >> ERK Nuclear and 
cytosolic 
 
Several knockout mice deficient in MKPs have been generated. The studies on 
these mice revealed that MKPs are important regulators in physiological processes. 
MKP-1 knockout (MKP-1-/-) mice were more sensitive towards LPS challenge in vivo 
compared to the wildtype mice. Upon LPS challenge, MKP-1-/- mice produced greater 
amounts of TNF-$, IL-1#, MCP-1, GM-CSF, IL-6, IL-10 and IL12p70 and had 
higher rate of organ failure and mortality compared to the wildtype mice 65,66. In 
addition, MKP-1-/- macrophages and dendritic cells produced more TNF-$ and IL-6 
compared to those of wildtype upon stimulation with LPS. The splenocytes of MKP-
1-/- mice also produced more TNF-$ but less IL-12 and IFN-! compared to the 
wildtype splenocytes 66. Meanwhile, a study on MKP-5 knockout (MKP-5-/-) mice 
showed that macrophages from these mice produced higher level of IL-6 and TNF-$ 
upon LPS stimulation compared to the wildtype macrophages. In adaptive immunity, 
MKP-5-/- mice exhibited reduced activation and proliferation of naïve T cells. In 
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addition, these mice also mounted more robust adaptive immune response through 
greater production of effector T cells cytokines compared to the wildtype mice 67. 
Lastly, DUSP2 knockout (DUSP2-/-) mice macrophages stimulated with LPS had 
lower level of transcripts encoding for pro-inflammatory mediators and cytokines 
such as IL-6, IL-12$, IL-1# and COX-2 68. 
1.5.1. MAPK Phosphatase-3 (MKP-3) 
MKP-3, also known as DUSP6, is a MAPK phosphatase which has high 
specificity towards ERK 69,70. MKP-3 has been reported to play important roles in 
embryonic development, immune response and cancer. During vertebrate limb 
development, expression of MKP-3 induced by fibroblast growth factor (FGF) 
prevents cell death in the mesenchyme by downregulation of ERK phosphorylation 71. 
This shows that MKP-3 mediates the signalling pathway in mesenchymal 
proliferation and apoptosis during limb development. MKP-3 knockout (MKP-3-/-) 
mice embryos had increased ERK phosphorylation especially in the limb buds, and 
the pups developed skeletal dwarfism, coronal craniosynostosis and hearing loss. Loss 
of MKP-3 also caused postnatal lethality in some of the pups 72. This shows MKP-3 
plays a role in development, but other mechanisms may exist to compensate the loss 
of MKP-3. 
In the immune response, MKP-3 was shown to affect a productive T cell 
activation. In elderly individuals, increased expression of MKP-3 due to decreased 
miR-181a resulted in the dampening of ERK activation in CD4+ naïve T cells. This 
resulted in the reduced number of TCR-induced activated T cells, causing weaker 
immune response to antigenic peptide exposure 73. In mice, naïve T cell exposure 
towards LPS was shown to induce MKP-3 expression upon TCR stimulation. This 
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resulted in reduced ERK phosphorylation and cytokine production 74. Taken together, 
these studies showed MKP-3 as an important molecule in modulating TCR signalling 
and subsequent T cell activation. 
In pancreatic cancer, MKP-3 was found to be upregulated in dysplastic 
carcinoma cells but downregulated in invasive and poorly differentiated carcinoma 
cells. In the same study, expression of MKP-3 using adenoviral vector suppressed cell 
growth in pancreatic cancer cell lines 75. Another study found that MKP-3 was 
downregulated on protein level in ovarian cancer samples compared to healthy 
samples. In ovarian cancer cell lines, MKP-3 was shown to negatively regulate cell 
proliferation and anchorage-dependent growth ability 76. Similarly in lung cancer cell 
lines, MKP-3 overexpression downregulated ERK phosphorylation which resulted in 
growth arrest and apoptosis 77. Taken together, these studies demonstrate the role of 
MKP-3 as a negative regulator of tumour progression through inhibition of cell 
proliferation and survival. 
1.6. Study Rationale and Objectives 
The pathogenesis of intestinal inflammation is a result of complex interaction 
between the mucosa epithelia and the luminal content. The mucosa epithelial barrier 
not only acts as a critical mediator for the transmission of signal from the lumen to 
underlying immune compartment but also serves as an important physical barrier 
protecting the immune compartment from luminal toxins and gut microbiota 78. One 
key regulatory pathway involved in this interaction is the MAPK signalling pathway. 
A previous study on one MKP member, MKP-1, suggested the regulation of MAPKs 
in gut immune cells during intestinal inflammation by MKPs, in conjuction with the 
loss of IL-10 79. On the other hand, it is well established that the ERK regulatory 
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pathway plays an important role in epithelial cell functions such as the IEC restitution 
and cell proliferation, which helps maintain IEC barrier function 55.  
Previous work in our group has shown the importance of ERK-MKP interaction 
in intestinal inflammation. MKP-5-/- mice developed less severe intestinal 
inflammation compared to the wildtype mice as a result of increase in intestinal 
barrier function through increase in ERK-KLF5 signalling (unpublished data). In 
addition, a single pilot experiment also showed that MKP-3-/- mice were less 
susceptible to colitis compared to the wildtype control when subjected to 2% DSS 
treatment for 7 days 80. This result indicates that MKP-3 potentially has a negative 
regulatory role in DSS-induced colitis. Adding to the observation that MKP-3 
specifically dephosphorylates ERK, which plays an important role in cell proliferation 
and restitution, we speculate that MKP-3 may play an important role in intestinal 
epithelial barrier integrity by inhibition of ERK and hence cell proliferation. 
Therefore this study aims to achieve the following objectives: 
1. To examine the role of MKP-3 in IEC in response to chemical insult and 
bacterial toxin, in relation to MAPKs activation and expression of pro-
inflammatory genes, 
2. To examine the effect of MKP-3 on cell proliferation and wound healing 
ability in IEC and 
3. To investigate the effect of DSS induced colitis in MKP-3-/- mice.  
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2. Materials and Methods 
2.1. Cell Culture 
The mouse rectal carcinoma cell line CMT93 (American Type Culture 
Collection, USA) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS) (Gibco, USA) and 1% Penicillin 
Streptomycin (Gibco). The cells were maintained in T75 flasks (Nunc, Denmark) in a 
humidified chamber at 37°C with 5% CO2 and passaged upon confluency.  
During passaging, the cells were treated with 0.25% Trypsin-EDTA (Gibco) 
and incubated at 37°C until all cells detached from the bottom of the flask and were 
then pelleted by centrifugation at 1,200 rpm for 5 mins using Allegra X-22R 
centrifuge (Beckman Coulter, USA). Cell suspension was diluted in Trypan Blue 
(Lonza, Switzerland) to determine cell viability. Cell counting was performed using a 
hemacytometer (Marienfeld, Germany).  
A CMT93 stable cell line overexpressing mouse MKP-3 was generated as 
previously described 80 and was maintained in 800 µg/ml G418 sulfate (US 
Biological, USA) in DMEM.  
CMT93 cells stably overexpressing MKP-3 (MKP3-CMT93) and its pcDNA 
transfected control cells (pcDNA-CMT93) were treated with 10 µg/ml LPS or 2% 
(w/v) DSS. LPS (Sigma, USA) and DSS powder (36-50 kDa, MP Biomedicals, USA) 
was diluted in serum free RPMI1640 (Gibco) and filter-sterilised before further 
application in cell culture. 
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2.2. RNA Isolation and Analysis 
Total RNA from cells and colon tissues was extracted using TRIzol® 
(Invitrogen, USA) according to the manufacturer’s instruction with some variations as 
follows. Cells were harvested in 500 µl TRIzol® followed by homogenisation with 
100 µl chloroform. The aqueous phase of the solution was harvested by centrifugation 
at 13,200 rpm for 15 mins before RNA precipitation with 1 volume of isopropanol. 
Total RNA was precipitated by centrifugation at 13,200 rpm for 10 mins and the RNA 
pellet was washed in 700 µl 75% ethanol by centrifugation at 13,200 rpm for 5 mins. 
All centrifugation was performed with Sorvall Legend Micro 21R centrifuge (Thermo 
Scientific, USA). The air-dried RNA pellet was reconstituted in 30 µl of DEPC-
treated water (Invitrogen).  
Colon tissues were homogenised in 1.0 mm zirconium oxide beads (Next 
Advance, USA) using Bullet Blender (Next Advance) set at maximum speed for 10 
mins or until no visible pieces of tissue remained. The remaining of the procedure was 
carried out as per RNA extraction procedure for cells. As DSS is an inhibitor of DNA 
polymerase 81, total RNA extracted from colonic tissues was further purified from 
DSS using Dynabeads mRNA Purification Kit (Invitrogen) according to the 
manufacturer’s instruction.  The concentration of RNA was determined using BioTek 
Synergy H1 Hybrid Multi-Mode Microplate Reader (BioTek Instruments, USA). 
For cDNA synthesis, 1 µg of total RNA from cells and 150 ng of purified 
mRNA from colon tissues were reversed transcribed using ImProm-II™ Reverse 
Transcription System (Promega, USA) in 20 µl volume. The resulting cDNA was 
kept at -20°C until they were ready for use. 
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Amplification of specific regions of desired transcripts were carried out in a 
mixture containing 1" iTaq™ Universal SYBR® Green Supermix (Bio-Rad, USA) 
and 0.25 µM forward and reverse primers (Table 2.1) in a 10 µl volume. The reaction 
was performed using Bio-Rad CFX ConnectTM Real-Time PCR Detection System 
(Bio-Rad) with the cycling conditions as follows: 95°C for 3 mins, and at 95°C for 10 
s and 60°C for 30 s for 40 cycles. 
Table 2.1 Sequences of primers used to detect mRNA transcript level by qPCR. 
Transcripts Primer sequence 
Actb Forward 5’-AGC ACT GTG TTG GCA TAG AGG TC-3’  
 Reverse 5’-CTT CTT GGG TAT GGA ATC CTG TG-3’ 
Ccl2 Forward 5’-CTC AGC CAG ATG CAG TTA ACG CCC-3’  
 Reverse 5’-GGT GCT GAA GAC CTT AGG GCA GAT-3’ 
Ccnb1 Forward 5’-AAG CAC ATG ACT GTC AAG AAC AA-3’ 
 Reverse 5’-AGC CTA AAC TCA GAA GCA ACA-3’ 
Ccnd1 Forward 5’-GGA GCT GCT GCA AAT GGA AC-3’ 
 Reverse 5’-TCA TCC GCC TCT GGC ATT TT-3’ 
Cdx1 Forward 5’-GAC CCG AAC CAA GGA CAA GT-3’ 
 Reverse 5’-GAT CTT TAC CTG CCG CTC TGT-3’ 
Cdx2 Forward 5’-CCC TAG GAA GCC AAG TGA AAA C-3’ 
 Reverse 5’-CTC TGC GGT TCT GAA ACC AA-3’ 
Cxcl1 Forward 5’-AAC CGA AGT CAT AGC CAC ACT-3’  
 Reverse 5’-CCG TTA CTT GGG GAC ACC TT-3’ 
Il10 Forward 5’-GCT CTT ACT GAC TGG CAT GAG-3’ 
 Reverse 5’-CGC AGC TCT AGG AGC ATG TG-3’ 
Il1b Forward 5’-CAA CCA ACA AGT GAT ATT CTC CAT G-3’  
 Reverse 5’-ATC CAC ACT CTC CAG CTG CA-3’ 
Il17a Forward 5’-GCT CCA GAA GGC CCT CAG A-3’ 
 Reverse 5’-AGC TTT CCC TCC GCA TTG A-3’ 
Il6 Forward 5’-GAT GCT ACC AAA CTG GAT ATA ATC-3’  
 Reverse 5’-TGT ACT CCA GGT AGC TAT G-3’ 
Klf4 Forward 5’-CCG ACT AAC CGT TGG CGT-3’ 
 Reverse 5’-CGG GTT GTT ACT GCT GCA AG-3’ 
Klf5 Forward 5’-AGC GAC GTA TCC ACT TCT GC-3’ 
 Reverse 5’-GCT TCT CGC CCG TAT GAG TC-3’ 
Tgfb1 Forward 5’-ACC GGA GTT GTG CGG CAG TG-3’ 
 Reverse 5’-GCC GGT AGT GAA CCC GTT GAT GT-3’ 
Tnf Forward 5’-TCC CAG GTT CTC TTC AAG GGA-3’  
 Reverse 5’-GGT GAG GAG CAC GTA GTC GG-3’ 
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2.3. Western Blotting 
2.3.1. Protein Extraction 
Culture media was removed from the wells followed by washing with 1" PBS. 
Cells were lysed in protein lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 1% NP-40, 
pH 7.8) containing protease inhibitor cocktail (Roche, Switzerland) and phosphatase 
inhibitor cocktail (Roche). The cells were harvested by scraping using a cell scraper 
and the lysate was vigorously mixed with a vortex machine. Soluble proteins were 
harvested by centrifugation at 13,000 rpm for 10 mins at 4°C and the supernatant 
containing total protein was kept at -80°C until it was ready for use.  
Colon tissues were homogenized with 1.0 mm zirconium oxide beads in 
complete protein lysis buffer using Bullet Blender tissue homogeniser. The tissues 
were homogenised for 10 mins at 4°C or until no pieces of tissues were visible, 
followed by incubation with gentle agitation for 30 mins at 4°C. The soluble proteins 
were harvested by centrifugation at 13,200 rpm for 10 mins at 4°C and the 
supernatant containing total protein was kept at -80°C until it was ready for use. All 
centrifugation was performed with Sorvall Legend Micro 21R centrifuge (Thermo 
Scientific).  
Total protein quantification was carried out using Bradford reagent (BioRad). 
The protein standards were prepared from 0.1 mg/ml Bovine Serum Albumin (BSA) 
solution in water. The standard protein concentrations used were 0, 10, 20, 30, 40 and 
50 µg/ml and the protein samples were diluted 200" in water. Absorbance at 595 nm 
was read using BioTek Synergy H1 Hybrid Multi-Mode Microplate Reader. 
Following protein quantification, the protein lysates were mixed with 4" protein 
loading dye (250 mM Tris, 8% SDS, 2% #-mercaptoethanol, 50% glycerol, pH 6.8) 
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and boiled at 95°C for 10 mins to denature the protein secondary and tertiary 
structures. 
2.3.2. SDS-PAGE and Protein Transfer 
The protein samples were separated through 10 or 12% polyacrylamide gel with 
constant current at 50 mA per gel in 1" running buffer (192 mM glycine, 25 mM Tris 
base, 0.1% SDS). After separation, the protein on the acrylamide gel was transferred 
onto a PVDF membrane (Millipore, USA) in 1" transfer buffer (192 mM glycine, 25 
mM Tris base, 0.1% SDS) at 100 V for 70 mins.  
2.3.3. Protein Detection and Analysis 
The PVDF membrane was blocked with 5% low fat milk (Anlene, New 
Zealand) in 1" TBST (20 mM Tris base, 137 mM NaCl, 0.1% Tween 20) for 1 hr at 
room temperature and subsequently incubated in primary antibody for overnight at 
4°C. After primary antibody incubation, the membrane was washed for 4 " 15 mins in 
1" TBST followed by incubation in 1:4000 anti-rabbit HRP-conjugated secondary 
antibody (NA934, GE Healthcare, UK) in 5% milk in 1" TBST for 1 hr at room 
temperature. Afterwards, the membrane was washed for 4 " 15 mins in 1" TBST. 
Bound antibodies were stripped from PVDF membranes by incubation in 
stripping buffer (20 mM glycine, 0.05% Tween 20, pH 2.5) for 10 minutes at 80°C, 
followed by blocking in 5% low fat milk in 1" TBST for 15-30 mins at room 
temperature. 
The chemiluminescent signal was developed using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, USA) or Clarity Western ECL Substrate 
(BioRad) depending on the strength of the signal. The chemiluminescent signal was 
developed on Amersham Hyperfilm ECL (GE Healthcare). 
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Table 2.2 List of primary antibodies used for Western blotting. 
Protein target Antibody dilution and diluent Manufacturer and cat. no. 
#-Actin 1:1000 in 5% milk in 1" TBST Cell Signalling #4970 
DUSP6 1:1000 in 5% milk in 1" TBST Abcam #ab76310 
ERK 1:1000 in 2.5% milk/BSA in 1" TBST Cell Signalling #4695 
pERK 1:1000 in 2.5% milk/BSA in 1" TBST Cell Signalling #4377 
JNK 1:1000 in 2.5% milk/BSA in 1" TBST Cell Signalling #9252 
pJNK 1:1000 in 2.5% milk/BSA in 1" TBST Cell Signalling #4671 
KLF5 1:1000 in 5% milk in 1" TBST R&D Systems #AF3758  
p38 1:1000 in 2.5% milk/BSA in 1" TBST Cell Signalling #9212 
pp38 1:1000 in 2.5% milk/BSA in 1" TBST Cell Signalling #9215 
 
2.4. Wound Healing Assay 
pcDNA-CMT93 and MKP3-CMT93 were seeded at 1.5 " 106 cells/well into 6-
well plates. The cells were allowed to attach overnight before 2% DSS treatment for 
24 hrs. Afterwards, the cells were washed with complete DMEM for 3 times. After 
the second wash, the bottom of each well were marked with one vertical line dividing 
the wells into two equal halves and 6 horizontal lines dividing the vertical line into 7 
approximately equal parts with a scalpel blade. These lines served as a guide for the 
wound gap measurement. At the third wash, a scratch wound was made alongside the 
vertical line with a 10 µl pipette tip, followed by a last wash. Both “untreated” and 
“with recovery” wells were added with complete DMEM while “no recovery” wells 
were added with 2% DSS.  
 
Figure 2.1 Diagram illustrating the markings for wound healing assay. 
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Micrographs of the wound gaps were taken at 0 hr and 6 hr after scratch was 
made using camera-fitted Olympus IX80 microscope. The wound gaps were 
measured using the Ruler Tool in Adobe® Photoshop® CS5 software. 
2.5. Proliferation Assay 
pcDNA-CMT93 and MKP3-CMT93 were seeded at a density of 0.4 " 106 in 6-
well plates and were let to attach overnight. Serum starvation of cells was done as 
previously described 82. The cells were incubated overnight in serum-free DMEM. On 
the following day (0 hr), the serum-free DMEM was replaced with complete DMEM 
with or without 2% DSS. For direct growth method, the cells were incubated 
overnight in complete DMEM. On the following day (0 hr), the complete DMEM was 
replaced with complete DMEM with or without 2% DSS.  
At the end of each time point (i.e. 0 hr, 24 hrs, 48 hrs and 72 hrs), the cells were 
fixed in ice-cold methanol and let to air-dry. The fixed cells were kept at 4°C until 
they were ready for staining. The cells were stained in 0.5% crystal violet in 20% 
methanol for 10 mins, followed by washing in RO water to remove all unbound dyes. 
Bound dyes were solubilised with 0.1 M sodium citrate in 50% ethanol and the colour 
intensity was measured by absorbance at 540 nm. 
2.6. Animal Studies 
Animal studies were performed in accordance with the National University of 
Singapore (NUS) Institutional Animal Care and Use Committee (IACUC). The 
procedures used in this study were approved under the IACUC protocol number 
111/09. Wildtype C57BL/6 and MKP-3 knockout (MKP-3-/-) mice were obtained 
from the Centre of Animal Resources (CARE) of NUS and Jackson Laboratories 
(USA), respectively and were bred under specific pathogen-free (SPF) conditions. 
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The mice were housed under controlled temperature (25°C) and photoperiods 
(alternating 12 hrs of light and dark cycle) and were fed with standard diet. For each 
group of experiment, mice were age- and sex-matched. Before the start of the 
experiments, the male mice weighed between 24.5 g and 26.7 g (mean = 25.7 g), 
while the female mice weighed between 17.3 g and 21.6 g (mean = 19.8 g). 
Eight-week old C57BL/6 mice and MKP-3-/- mice were given 2% DSS in 
drinking water ad libitum for 7 days to induce intestinal inflammation (n = 2 mice in 
each group). Weight changes in the mice were recorded daily. At the end of the 
treatment, the mice were sacrificed by asphyxiation with CO2. Severity of colitis was 
assessed via weight change and histology assessment. Upon sacrifice, the colon 
tissues were cut open longitudinally into two equal parts. One part of the colon was 
used for histological analysis, and the other part was harvested for mRNA and protein 
extraction. 
2.6.1. Histological Analysis 
Colon tissues were fixed in 10% formalin and were processed in Leica TP1020 
tissue processor (Leica Biosystems, Germany) in the sequence as follows: 70% 
ethanol for 1 hr, 80% ethanol for 1 hr, 90% ethanol for 1 hr, 3 " 100% ethanol for 1.5 
hrs, 2 " Histo-Clear (National Diagnostics, USA) for 2 hrs and 2 " wax for 2.5 hrs. 
Processed tissue were subsequently embedded in paraffin. The tissues were cut into 5 
µm sections using Leica RM2255 (Leica Biosystems) and mounted onto microscope 
glass slides. To visualize the extent of immune cells infiltration and inflammation, the 
sections were stained with Haematoxylin and Eosin (H and E). Micrographs of the 
stained slides were taken with camera-fitted Leica DM2000 microscope (Leica 
Biosystems). Colitis in mice was scored in blinded manner and was based on colonic 
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crypt architecture, presence/absence of crypt abscesses, level of tissue damage, goblet 
cell loss and inflammatory cell infiltration (Supplementary Table 1). 
2.6.2. Ki67 Immunohistochemistry 
Formalin fixed and paraffin embedded colon tissue sections were deparaffinised 
in Histochoice clearing agent (Sigma) for 10 mins followed by rehydration in 
reducing ethanol series as follows: 2 % 100% ethanol for 2 mins, 95% ethanol for 2 
mins and 70% ethanol for 2 mins. Antigenic retrieval was subsequently carried out in 
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for 20 mins at 
boiling temperature followed by treatment with 3% hydrogen peroxide and blocking 
with 3% BSA in PBS for 10 mins. Detection of Ki67 was carried out by incubation in 
biotin-conjugated Ki67 primary antibody (eBioScience, USA) (1:100 in 3% BSA in 
PBS) for overnight, followed by streptavidin-HRP secondary antibody (Biolegend, 
USA) (1:200 in 3% BSA in PBS) for 1 hr. Peroxidase signal was developed with 
DAB substrate (Dako, Denmark) followed by counterstaining with hematoxylin to 
visualise the nuclei for 30 s. Dehydration was carried out in 70% ethanol for 2 mins, 
95% ethanol for 2 mins and 2 % 100% ethanol for 2 mins. The stained sections were 
then mounted with Histomount mounting reagent (Invitrogen). For quantification of 
Ki67 staining, 10 to 15 full-length crypts adjacent to ulcerated regions were analysed. 
Total Ki67 positive cells were expressed as percentage to the total number of nucleus 
per full-length crypt. 
2.7. Statistical Analysis 
Two-tailed unpaired t test was performed using GraphPad Prism version 5.0 
software. Differences were considered significant when P < 0.05. 
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3. Results 
3.1. MKP-3 Negatively Regulates Inflammatory Response in 
CMT93 cells 
A previous work by our laboratory showed that MKP-3 was upregulated in 
CMT93 cells upon LPS and DSS treatment (Supplementary Fig 1) 80. To confirm the 
role of MKP-3 in the inflammatory response of IEC against LPS and DSS, MKP3-
CMT93 and pcDNA-CMT93 were treated with 2% DSS and 10 µg/ml LPS. The 
effect of MKP-3 overexpression on MAPKs phosphorylation was examined. In 
addition, the inflammatory response of these cells was also assessed via the level of 
pro-inflammatory chemokines and cytokines transcripts in the cells.  
Upon DSS and LPS treatment, MKP3-CMT93 showed reduced phosphorylation 
of ERK, JNK and p38 compared to pcDNA-CMT93 (Fig 3.1A). The inhibition was 
observed consistently throughout all of the time points of the treatment. CXCL1 
(encoded by Cxcl1) is a neutrophil chemoattractant and has been shown to induce 
neutrophil infiltration into the colon epithelium during intestinal inflammation 83,84. 
MCP-1 (encoded by Ccl2), on the other hand, induces monocyte and macrophage 
infiltration 85,86. Also, TNF-$ (encoded by Tnf) is known to be an important mediator 
in IEC apoptosis and survival during intestinal inflammation 87. We then measured the 
expression level of these genes to determine if MKP-3 affects the pro-inflammatory 
response of CMT93 upon LPS and DSS stimuli. We observed that the level of Cxcl1, 
Ccl2 and Tnf transcripts were reduced between 6- to 33-fold in MKP3-CMT93 upon 
LPS and DSS treatment compared to the pcDNA-CMT93 at both 3 hrs and 6 hrs time 
points (Fig 3.1B). Taken together, these results showed that MKP-3 downregulates 
not only MAPKs activation but also the expression of several key pro-inflammatory 
genes in intestinal inflammation in response to LPS and DSS stimuli in CMT93 cells. 
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Figure 3.1 Overexpression of MKP-3 reduced MAPK activation and pro-
inflammatory genes expression in CMT93 cells. CMT93 cells were treated with 2% 
DSS or 10 µg/ml LPS for 3 hrs and 6 hrs. MAPK activation and pro-inflammatory 
genes expression were analysed via Western blot and qPCR, respectively. (A) 
Western blots of MAPK activation after DSS and LPS stimulation in pcDNA-CMT93 
and MKP3-CMT93. Western blots are representative of three independent 
experiments. (B) Pro-inflammatory cytokine and chemokines transcript level in 
pcDNA-CMT93 and MKP3-CMT93 upon DSS and LPS stimulation. Bar charts show 
means and standard deviations from two independent experiments. * P < 0.05, ** P < 
0.01 and *** P < 0.001 with unpaired t test. 
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3.2. MKP-3 Regulates Epithelial Cell Proliferation and Migration 
In Vitro 
Since MKP-3 dephosphorylates ERK, an important regulator in cell 
proliferation and migration, we examined the effect of MKP-3 overexpression on the 
rate of cell proliferation. A cell proliferation assay was performed over 24-72 hrs on 
the MKP3-CMT93 and pcDNA-CMT93 with or without 2% DSS treatment. In the 
direct growth method, the cells were seeded one day prior to the start of the assay and 
the following day was considered as 0 hr. With this method, MKP3-CMT93 
proliferated about 3.5 fold less than pcDNA-CMT93 at 72 hrs when grown in normal 
media (P < 0.001). Upon treatment with 2% DSS, MKP3-CMT93 proliferated about 2 
fold less than pcDNA-CMT93 at 72 hrs (P < 0.01) (Fig 3.2). In serum-starved 
method, the cells were serum starved for 24 hrs after seeding in order to allow growth 
arrest in the cells. The addition of serum at 0 hr was expected to induce robust cell 
growth. MKP3-CMT93 proliferated 0.5 fold less compared to the pcDNA-CMT93 
without 2% DSS treatment at 24 hrs (P < 0.001). With 2% DSS treatment, MKP3-
CMT93 proliferated 0.4 fold less compared to the pcDNA-CMT93 at 24 hrs (P < 
0.001) (Fig 3.2). Therefore taken together, these results suggest the negative role of 
MKP-3 in cell proliferation.  
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Figure 3.2 Overexpression of MKP-3 reduced epithelia proliferation in CMT93 
cells. Bar chart shows the proliferation rate of pcDNA-CMT93 and MKP3-CMT93 
with or without DSS treatment with direct growth and serum-starved growth method. 
CMT93 cells were treated with or without 2% DSS for various time points and the 
proliferation rate was measured via crystal violet staining. Bar charts show means and 
standard deviations from two independent experiments. * P < 0.05, ** P < 0.01 and 
*** P < 0.001 with unpaired t test. 
To examine the wound healing ability of the cells, MKP3-CMT93 and pcDNA-
CMT93 were seeded to confluence with or without 2% DSS treatment, after which a 
scratch was made, followed by treatment or no treatment with 2% DSS. The extent of 
wound closure at 6 hrs post-scratch was measured. MKP3-CMT93 showed 6-10% 
less wound healing ability compared to the pcDNA-CMT93 when treated with 2% 
DSS prior to (with recovery, P < 0.01) or prior to and after (no recovery, P < 0.01) the 
scratch. Meanwhile, in the absence of DSS insult, pcDNA-CMT93 showed about 
28% better wound healing ability compared to MKP3-CMT93 when grown in normal 
media (P < 0.01) (Fig 3.3A). These results suggest the role of MKP-3 in mediating 






Figure 3.3 Overexpression of MKP-3 reduced epithelia migration in CMT93 cells. (A) Bar charts and (B) representative micrographs 
showing wound healing ability of pcDNA-CMT93 and MKP3-CMT93 in various conditions. A scratch was made on CMT93 cells to create a 
wound, and the extent of the wound closure was measured by the difference in the wound gap immediately after scratch and after 6 hrs. 
“Untreated” indicates no treatment of 2% DSS, “with recovery” and “no recovery” indicate no treatment and treatment of 2% DSS, respectively, 
during 6 hrs wound healing period. Bar charts show means and standard deviations and are representative of three independent experiments. 
Micrographs are representative of three independent experiments. ** P < 0.01 with unpaired t test. Scale bars represent 100 µm. 
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Krüppel-like factor 4 (KLF4) and Krüppel-like factor 5 (KLF5) are zinc-finger-
containing transcription factors which are highly expressed in the intestinal 
epithelium 88. It was previously reported that KLF4 knockout (KLF4-/-) mice showed 
defect in the differentiation of goblet cells in the colon 89. Meanwhile, intestinal-
specific deletion of Klf5 resulted in neonatal death accompanied by the absence of 
IEC proliferation 90. Also, heterozygous KLF5 knockout (KLF5+/-) mice showed 
reduced IEC proliferation and migration compared to its wildtype counterparts during 
recovery period after DSS treatment 91. These findings suggest an important role of 
these genes in intestinal epithelial repair and homeostasis. We therefore measured the 
level of Klf4 and Klf5 expression in DSS-treated pcDNA-CMT93 and MKP3-CMT93 
to determine if these genes are involved in the proliferation and wound healing 
process in these cells after DSS treatment. Our analysis showed lower expression of 
Klf4 (P < 0.01) and Klf5 (P < 0.05) at 3 hrs of DSS treatment in MKP3-CMT93 
compared to pcDNA-CMT93 (Fig 3.4). This result further shows that MKP3-CMT93 
had less cell proliferation compared to pcDNA-CMT93, possibly through the 
regulation of the expression of these genes. 
 
Figure 3.4 Overexpression of MKP-3 decreased the expression of Klf4 and Klf5 in 
response to DSS stimuli. pcDNA-CMT93 and MKP3-CMT93 were treated with 2% 
DSS for 3 hrs, and the expression of Klf4 and Klf5 were measured via qPCR. Bar 
charts show means and standard deviations from two independent experiments. * P < 
0.05 and ** P < 0.01 with unpaired t test.  
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3.3. Loss of MKP-3 Results in Less Severe Colitis 
Next, we examined the role of MKP-3 in intestinal inflammation in vivo. Male 
and female wildtype and MKP-3-/- mice were treated with 2% DSS for 7 days to 
induce intestinal inflammation in the mice. The weight of the mice was recorded 
daily. At the end of the treatment, the mice were culled and the colon tissues were 
harvested for examination.  
The weight loss in the wildtype mice started from day 4 and continued until the 
end of the treatment. This is in accordance to the hallmark feature of DSS-induced 
colitis model where DSS-treated mice lose weight in time-dependent manner 92. 
However, the weight of MKP-3-/- mice was not affected by the DSS treatment and 
was maintained in the male mice and increased in the female mice throughout the 
course of the treatment (Fig 3.5A). Histological analysis showed severe inflammation, 
goblet cell loss and loss of crypt architecture in the wildtype mice. However, the 
colon of the MKP-3-/- mice, although inflamed, showed much less crypt damage and 
goblet cell loss as well as more well-preserved crypt architecture compared to the 
colon of wildtype mice (Fig 3.5B). In addition, blinded histological scoring based on 
goblet cell loss, crypt architecture and infiltration of immune cells showed lower 




Figure 3.5 MKP-3-/- mice were less susceptible to DSS-induced colitis. (A) The weight change of DSS-treated wildtype and MKP-3-/- mice 
was monitored everyday for 7 days. The line graph shows means and standard deviations from two (male) and four (female) mice from each 
group. (B) H and E stain of the mice colon tissues and their corresponding histology score to show the extent of inflammation in DSS-treated 
wildtype and MKP-3-/- mice. Higher magnification of each boxed area is shown below each micrograph. The micrographs are taken under bright 
field microscopy and are representative of two (male) and four (female) mice from each group. The scale bars represent 100 µm.  
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We then measured the expression level of several chemokines and cytokines 
which were previously known to be upregulated in the DSS-induced colitis model. As 
described previously in section 3.1., Cxcl1 and Ccl2 encode for neutrophil and 
macrophage chemoattractants, respectively 83–86. Also, besides determining IEC 
survival and apoptosis, Tnf is important for the progression of DSS-induced colitis 
model 93. Meanwhile, Il1b and Il6 are predominantly expressed by macrophages and 
are important cytokines in the initiation of intestinal inflammation 94,95. In addition 
Il17a and Tgfb1 expression were previously known to induce Th17 differentiation, 
which suppresses Treg and drives inflammation in the intestines 19. IL-10-/- mice 
spontaneously develop colitis which shows that IL-10 is an important 
immunoregulator in the intestines 96. We found that the level of these inflammatory 
cytokines and chemokines transcripts were mostly reduced in both male and female 
MKP-3-/- mice, except for the level of Tnf and Il10 in the male mice, which was 
similar in both groups of mice (Fig 3.6). This result indicates that the colonic 
inflammation in the MKP-3-/- mice was less severe compared to the wildtype mice. 
Meanwhile, the phosphorylation of ERK in the colon was also enhanced in the MKP-
3-/- mice compared to the wildtype mice. However, the phosphorylation of JNK and 
p38 was similar in both groups of the female mice and the phosphorylation of JNK 
was slightly reduced in the MKP-3-/- male mice (Fig 3.7). 
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Figure 3.6 Reduced pro-inflammatory chemokines and cytokines gene 
expression in MKP-3-/- mice colon after DSS treatment. The expression of 
inflammatory genes in the colon tissues of DSS-treated wildtype and MKP-3-/- mice 
were measured via qPCR. Dot plots show individual values, means and standard 
deviations from two (male) and four (female) mice from each group. * P < 0.05,  ** P 
< 0.01 and *** P < 0.001 with unpaired t test. 
 
Figure 3.7 MKP-3-/- mice had increased ERK activation in the colon after DSS 
treatment. The MAPK activation in the colon tissues of DSS-treated wildtype and 
MKP-3-/- mice were analysed via Western blot. Each lane represents one DSS-treated 
mouse. 
Taken together, these results demonstrate that MKP-3-/- mice had less severe 
colitis upon 7 days of 2% DSS treatment compared to the wildtype mice and that 
MKP-3 is an ERK phosphatase in the colon. This suggests that MKP-3 play a 
negative regulatory role in intestinal inflammation. 
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3.4. Increase in IEC-Associated Proliferation Genes in MKP-3-/- 
Mice after DSS Treatment 
Because MKP-3-/- mice had increased ERK activation and were less prone to 
colitis, we examined the state of cell proliferation in the colonic tissue by assessing 
the expression of several genes involved in proliferation and cell cycle. The 
transcription factors Cdx1 and Cdx2 are important in the development of intestinal 
epithelium and are also known to regulate cell proliferation in the IEC 97,98. 
Meanwhile, Cyclin B1 and Cyclin D1 regulate the progression of mitosis 99. We 
found that Cdx1 and Cdx2 transcript levels were about 10 times higher in the male 
MKP-3-/- mice compared to the wildtype mice and only about 3 times higher in the 
female MKP-3-/- mice compared to the wildtype mice. Meanwhile, Klf4 and Klf5 
transcript levels were about 3 times higher in both male and female MKP-3-/- mice 
compared to the wildtype mice (Fig 3.8A). On the protein level, the expression of 
KLF5 protein was higher in the MKP-3-/- mice (Fig 3.8B). (The specificity of KLF5 
antibody was confirmed with transient overexpression of KLF5 in CMT93 cell line, 
Supplementary Fig 2.).  
Furthermore, the mice colon tissues were stained for Ki67 to show the status of 
IEC proliferation in the colon. Ki67 is expressed during G1, S, G2 and mitosis phase 
of the cell cycle but not G0 and therefore has been widely used as a cell proliferation 
marker 100.  Ki67 staining of the mice colon showed 15% higher  (female mice, P < 
0.01) in the percentage of Ki67 positive cells per crypt in the MKP-3-/- mice compared 
to the wildtype mice (Fig 3.9). This shows that IEC proliferation was increased in the 
colon of MKP-3-/- mice. Taken together, these results suggest that MKP-3 regulates 
IEC proliferation during injury by regulating the expression of genes involved in cell 
proliferation and cell cycle. 
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Figure 3.8 Expression of proliferation genes and KLF5 protein was higher in 
MKP-3-/- mice colon after DSS treatment. (A) Expression of proliferation genes in 
the DSS-treated wildtype and MKP-3-/- mice colon tissues was measured via qPCR. 
Dot plots show individual values, means and standard deviations from two (male) and 
four (female) mice from each group. (B) Western blots showed the expression of 
KLF5 protein in the DSS-treated wildtype and MKP-3-/- mice colon tissues. Each lane 
represents one DSS-treated mouse. * P < 0.05 with unpaired t test. 
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Figure 3.9 MKP-3-/- mice had increased IEC proliferation compared to wildtype 
mice after DSS treatment. DSS-treated mice colon tissues were stained for Ki67 and 
counted for Ki67 positive cells per crypt. Micrographs show localised Ki67 staining at 
the base of the crypt where cells actively divide. The micrographs are representative 
of two (male) and three (female) mice. The scale bars represent 100 µm. Bar charts 
show mean and standard deviations from two (male) and three (female) mice. ** P < 
0.01 with unpaired t test.  
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4. Discussion 
The role of MKPs in inflammatory response of immune cells has been 
extensively studied 65–68,73,74. However, the role of MKPs in the regulation of MAPKs 
in IEC during inflammatory response is still unclear. In intestinal inflammation, the 
intestinal mucosa layer not only provides an important barrier separating the luminal 
microbiota from the immune cells in the lamina propria but also acts as a signalling 
mediator between the luminal content and the underlying immune cells. Disruption of 
this barrier function exposes the microbiota to the immune cells, which results in 
inflammation 78. The MAPK pathway is one of the mediators of inflammation and its 
negative regulation by MKPs is important in keeping the extent and duration of the 
inflammatory response in check. Therefore in the current study, we utilised a 
previously-established stable CMT93 cell line that overexpresses MKP-3 80 as well as 
subjected MKP-3-/- mice to DSS-induced colitis to examine the role of MKP-3 in IEC 
during intestinal inflammation.  
In DSS-induced colitis model, the intestinal epithelial barrier disruption was 
achieved by introducing DSS to the colon. Existing studies suggest that DSS forms 
pores in the otherwise sterile mucus layer, which allows bacteria to come in contact 
with IEC, hence causes inflammation 23. To mimic this effect in vitro, CMT93 cells 
were treated with DSS and LPS. MKP-3 overexpression was shown to downregulate 
the activation of all MAPKs in CMT93 stimulated with DSS and LPS (Fig 3.1A). 
MKP-3 has been shown to preferentially dephosphorylate ERK in vivo 70–72 and 
studies on MKP-3 substrate specificity in vitro has been focused on ERK 75–77. 
However, it is known that MKPs can have different substrate specificity in different 
organs, tissues and cell types in vitro and in vivo 67,68. In this study, protein analysis in 
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the mice showed that MKP-3 strongly affected ERK phosphorylation, but not JNK 
and p38 (Fig 3.7). For this reason, we focused on the effect of MKP-3 on ERK 
phosphorylation for the remaining in vitro experiments in this study. 
The non-specificity of MKP-3 towards MAPKs that we observed in vitro could 
be caused by hypermorphism where the overexpressed protein becomes functionally 
hyperactive because it is expressed above its normal physiological level in the cell 
101,102. Considering MKP-3 has physiologically low substrate specificity towards JNK 
and p38 44, high amount of MKP-3 in the cell could cause hyperactive binding of the 
molecule towards its usual less-preferred substrates. As a result, this could have 
caused the dephosphorylation of JNK and p38 in MKP3-CMT93. 
Overexpression of MKP-3 resulted in the decrease of pro-inflammatory genes 
expression upon DSS and LPS stimulation in CMT93 (Fig 3.1B). How DSS activates 
the MAPKs in the cell is still not well understood. Nevertheless, it is known that the 
recognition of LPS by TLR4 culminates in the phosphorylation of MAPKs through 
the MyD88-dependent pathway. Phosphorylated MAPKs then activate the 
transcription factors that drive the expression of pro-inflammatory genes 30. As a 
result of the downregulation of MAPKs activation by MKP-3, the transcriptional 
regulation of pro-inflammatory genes was also downregulated. This in vitro 
phenomenon could be attributed by the decrease in JNK and p38 as well as ERK 
phosphorylation. 
Meanwhile, in the intestines where epithelial cells are constantly being shed off, 
proliferation is an important process to replace the lost cells as a part of healthy gut 
homeostasis. Cell proliferation assays were conducted to examine the role of MKP-3 
in this process. Overexpression of MKP-3 resulted in the downregulation of ERK 
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phosphorylation (Fig 3.1A). As ERK drives cell proliferation and growth, the 
overexpression of MKP-3 negatively affected the proliferation rate of CMT93 cells 
(Fig 3.2). Two different methods of cell proliferation assay were used to confirm the 
results. In the direct growth method, cells were seeded and let to settle overnight in 
the presence of serum. In the serum-starved method, cells were seeded and let to settle 
overnight in serum-free condition. Serum starvation has been frequently carried out to 
arrest cell growth in cell cycle studies. In this experiment, the addition of serum after 
overnight starvation was expected to induce robust growth, which would widen the 
difference in proliferation rate between the two cell types. 
In the event of colonic epithelial injury, restitution is an important process 
besides cell proliferation in recovering the epithelia layer. As discussed in section 
1.3., restitution is a process whereby nearby cells migrate to the injured area to re-
establish barrier continuity. Therefore besides cell proliferation, cell migration also 
plays an important role in epithelial wound healing. In order to examine how MKP-3 
affects this process in IEC, wound healing assay was carried out. Overexpression of 
MKP-3 retarded cell migration in CMT93 cells (Fig 3.3A). This result indicates the 
involvement of MKP-3 in overall cell migration/restitution in IEC in vitro, both in the 
presence or absence of DSS insult. 
Overexpression of MKP-3 lowered the level of Klf4 and Klf5 transcripts upon 
DSS stimulation in vitro (Fig 3.4). Both of these genes encode for transcription 
factors that are highly expressed and regulate cell proliferation and differentiation in 
the IEC 88. Klf4 regulates goblet cells differentiation and maturation while KLF5 
maintains IEC proliferation, differentiation and cell positioning along the colonic 
crypt axis 88–90. In addition, KLF5 induction in IEC upon DSS stimulation in vitro was 
previously shown to involve ERK 91. Therefore it is possible that MKP-3 plays a role 
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in the expression of Klf5 by deactivating ERK and hence overexpression of MKP-3 
results in decreased cell proliferation and migration. Our study also suggested a 
regulatory role of MKP-3 in the expression of Klf4, which mechanism requires further 
investigation. 
In this study, CMT93 was used as an in vitro model for IEC. CMT93 is a 
polyploid carcinoma cell line which was isolated from rectum of a male C57BL/6 
mice 103. Being an epithelial cell line originating from a mice colon, this makes the 
cell line an appropriate in vitro model for studying the colon IEC responses to 
external stimuli and injury. However, there is also a limitation in that the cell line 
consists of a homogeneous carcinoma population and therefore would not accurately 
mimic normal IEC environment. In normal IEC homeostasis, old cells undergo 
apoptosis and are replaced by newly divided and differentiated cells from the stem 
cells at the bottom of the crypt. However in in vitro CMT93 model, the cells 
proliferate from a homogenous pool of cells. In addition, IEC in the colon consist of 
several types of cells such as stem cells, colonocytes and goblet cells, which together 
play a synergistic role in providing a protective barrier in the colon 104. Due to the 
homogeneity of CMT93 population of cells, the role of the interaction between the 
heterogenous cell populations in the colon could have been overlooked. 
After establishing the role of MKP-3 in IEC in vitro, DSS-induced colitis mice 
model was used to examine the role of MKP-3 in intestinal inflammation in vivo. The 
hallmark characteristic of this model was compared between the MKP-3-/- and 
wildtype mice to assess the difference in phenotype severity. The results from male 
and female mice were segregated due to greater susceptibility of male mice towards 
the DSS-induced colitis 105,106. The results showed that the wildtype mice developed 
more severe intestinal inflammation than the MKP-3-/- mice (Fig 3.5A, B, Fig 3.6). 
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Due to the less severe intestinal inflammation phenotype, it was expected that the 
level of anti-inflammatory gene transcripts such as Tgfb1 and Il10 be elevated in the 
MKP-3-/- mice. However, the level of these transcripts was also reduced alongside the 
other pro-inflammatory gene transcripts. This could be due to the lack of 
inflammatory response in the colon of MKP-3-/- mice and therefore the expression of 
these anti-inflammatory genes was not needed. Also, TGF-! is required for intestinal 
mucosal healing 107, but since there was less epithelial damage, the expression of 
Tgfb1 in the colon of MKP-3-/- mice may not be needed. In addition, besides acting as 
an anti-inflammatory cytokine, TGF-! is also required for the Th17 differentiation 
4,19,20. Therefore the low level expression of Tgfb1 may indicate less Th17 activation, 
which may cause less intestinal inflammatory response in the MKP-3-/- mice. 
Less susceptibility of the MKP-3-/- mice towards DSS treatment could be caused 
by reduced inflammatory response in the colon. Basal expression of Cxcl1 was 
downregulated in MKP-3-/- mice, however basal expression of the other inflammatory 
genes was comparable between the two groups of mice (Supplementary Fig 3A). 
CXCL1 knockout mice were previously shown to develop worse intestinal 
inflammation compared to the wildtype mice, albeit with the absence of neutrophil 
infiltration 83. This suggests that CXCL1 is important in the recruitment of neutrophil 
during intestinal inflammation, although its absence did not stop the development of 
intestinal inflammation. However, the absence of neutrophil infiltration could have 
caused more infiltration of other population of immune cells, thereby probably 
causing more severe inflammation in the colon of MKP-3-/- mice. In this study, the 
Cxcl1 was downregulated, but not completely absent, in untreated MKP-3-/- mice. 
This could have reduced the ability for neutrophil recruitment into the intestines, 
hence potentially desensitising the MKP-3-/- mice from intestinal inflammation 
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triggered by DSS. Therefore the lack of neutrophil recruitment into the intestines, 
together with better epithelial barrier integrity in the colon of MKP-3-/- mice, could 
have caused less tissue damage in the intestines in response to DSS injury. 
In addition to the downregulation of basal Cxcl1 expression in the MKP-3-/- 
mice, a pilot study done by our laboratory showed that bone marrow-derived 
macrophages (BMDM) from MKP-3-/- mice had lower level of inflammatory gene 
expression upon LPS stimulation (Supplementary Fig 4). This indicates that besides 
having reduced ability to recruit neutrophils and better intestinal epithelial barrier in 
response to DSS, MKP-3-/- mice immune cells such as macrophages have reduced 
inflammatory gene expression in response to TLR activation. This could further cause 
less inflammation in the intestines of MKP-3-/- mice. However, more studies are 
needed in order to confirm the role of the immune compartment of MKP-3-/- mice in 
intestinal inflammation. 
ERK phosphorylation was increased in the colon of MKP-3-/- mice (Fig 3.7). 
However, the amount of phosphorylated MAPKs in the colon does not come entirely 
from the IEC, as immune cells express MAPKs as well. However considering that 
there were less immune cell infiltration in the colon of MKP-3-/- mice (based on 
histological assessment, Fig 3.5B), it is reasonable to assume that the increase in ERK 
phosphorylation was mostly contributed by the IEC. Combined with our observation 
that MKP-3 negatively affects cell proliferation and restitution in vitro, we 
hypothesise that this phenotype was most likely contributed by increased epithelial 
barrier integrity mediated by increased phosphorylation of ERK in MKP-3-/- mice.  
As discussed in section 1.3., the intestinal epithelial repair is important in the 
event of an injury. The ability of the epithelia layer to rapidly heal itself is crucial in 
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preventing prolonged inflammation in the intestines. In vitro results in this study 
showed that when MKP-3 was overexpressed, cell proliferation and migration were 
delayed in CMT93 cells during DSS treatment. Therefore the absence of MKP-3 in 
MKP-3-/- mice would result in increased cell proliferation and migration in the IEC in 
the event of an injury. This would cause more rapid wound healing process of the 
intestinal mucosal layer when the mice colons were subjected to DSS insult. Because 
the intestinal barrier integrity was more well preserved in MKP-3-/- mice, the 
underlying immune compartment were less exposed to the luminal content, resulting 
in less severe colonic inflammation. 
Transcripts of proliferation genes and KLF5 protein were elevated in MKP-3-/- 
mice compared to the wildtype mice (Fig 3.8A, B). Although transcripts such as Cdx1 
and Cdx2 could come from infiltrating immune cells, the amount of these transcripts 
were still higher in MKP-3-/- mice which had less immune cell infiltration (based on 
histological assessment). In addition, the levels of Klf4 and Klf5 transcripts as well as 
KLF5 protein, which are enriched in IEC 88,108, were also increased in MKP-3-/- mice 
upon DSS treatment. These results suggest that cell proliferation and differentiation 
was enhanced in the colon of MKP-3-/- mice. Ki67 staining of the mice colon tissues 
further showed that there was increased IEC proliferation in the colon of MKP-3-/- 
mice compared to that of wildtype mice (Fig 3.9).  
Interestingly, the basal expression level of proliferation genes in the colon was 
comparable between wildtype and MKP-3-/- mice (Supplementary Fig 3B). This 
further shows that cell proliferation and differentiation in the colon of MKP-3-/- mice 
was only enhanced upon DSS treatment. This also indicates the role of MKP-3 in the 
regulation cell proliferation and differentiation in the colon in response to injury.  
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5. Future Directions 
The preliminary results of the current study highlight the potential important 
role of MKP-3 in the regulation of immune response especially in the IEC. There are 
several further studies that can be done in order to complement these current findings 
and to establish a more thorough understanding on the role of MKP-3 in intestinal 
inflammation. 
As the current study did not segregate the analysis of IEC from the infiltrating 
immune cells, the role of MKP-3 in each IEC and immune compartment in intestinal 
inflammation was unclear. Although the results suggested the role of IEC in intestinal 
inflammation, data from the immune compartment would further complement this 
finding. The IEC and immune cells from the colon can be separated using density 
separation and subsequent mRNA and protein from each compartment can be 
analysed separately. In addition, studies on Villin-Cre-MKP-3-/- mice with IEC-
specific deletion of MKP-3 and wildtype bone marrow transplant into MKP-3-/- mice 
would further differentiate the role of MKP-3 in the immune compartment from the 
IEC. These studies would provide a clearer picture of the cellular processes happening 
in each IEC and immune compartment separately. 
The next interesting area to study would be the immune cells characterisation 
from MKP-3-/- mice. As mentioned previously, the immune response is as equally 
important as the IEC response in intestinal inflammation. To characterise this, 
response of innate immune cells such as macrophages and dendritic cells towards 
TLR ligands and their subsequent ability to induce T cell responses should be 
investigated. Additionally, adaptive immune responses such as T cell activation and 
differentiation as well as T cell effector functions should be examined as well.  
  51 
The results from this study suggested the negative role of MKP-3 in cell 
proliferation and differentiation in the colon. Hyperproliferation usually results in 
uncontrolled cell growth and subsequently cancer. To show if MKP-3-/- mice have 
increased IEC proliferation, the azoxymethane (AOM)/DSS murine model can be 
utilised. In this model, the administration of AOM and DSS induces tumour 
development in the mice colon. If the hypothesis that MKP-3-/- mice have enhanced 
IEC proliferation is true, it is expected that MKP-3-/- mice would have enhanced 
tumour formation in the colon compared to wildtype mice. In addition, a recent study 
reported association between MKP-3/DUSP6 and rectal tumours cases with TP53 
mutation 109. This indicates a potential role of MKP-3 in tumour formation in the 
colon, which warrants further investigation.  
So far, there has not been a study linking the expression of MKP-3 in the 
intestines with human IBD cases. As the results of this study suggest the negative 
regulatory role of MKP-3 in intestinal inflammation, it would be interesting to 
examine the expression level of MKP-3 in the intestines of IBD patients. In addition, 
the absence of MKP-3 in the mice in this study seemed to show higher proliferation 
rate of the IEC upon chemical insult, which could also potentially play a part in 
tumour formation in the colon especially upon carcinogen exposure. Several studies 
have shown increased mRNA expression of MKP-2, MKP-3 and MKP-5 in colon and 
colorectal tumour from cancer patients 110–112. The findings from mice and human 
data seem to be contradictory. Nevertheless, this increase could be as a result of 
increased ERK phosphorylation, which suggests a negative feedback regulation. 
Therefore studying the regulation of these MKPs in the cancer cells could provide a 
better understanding of the regulatory mechanism of cell proliferation in colonic 
tumorigenesis and help in identifying new therapeutic targets for colon cancer. 
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6. Conclusion 
The results from this study have shown the role of MKP-3 in regulating 
intestinal inflammation. In vitro experiments showed that overexpression of MKP-3 
in IEC downregulated the phosphorylation of ERK, JNK and p38, and the pro-
inflammatory response towards DSS and LPS stimuli. The overexpression of MKP-3 
also retarded cell proliferation and migration along with lowering the expression of 
Klf4 and Klf5. Upon DSS treatment, MKP-3-/- mice developed less severe 
inflammation in the colon compared to the wildtype mice. The phosphorylation of 
ERK was enhanced and pro-inflammatory genes expression was reduced in the colon 
of MKP-3-/- mice. In addition, the expression of proliferative genes and KLF5 protein 
were higher in MKP-3-/- mice, accompanied with increased IEC proliferation in the 
colon of MKP-3-/- mice. Combined with the in vitro data, this suggests MKP-3 as a 
negative regulator in intestinal inflammation. 
The intestinal mucosa layer is important not only as a physical barrier but also 
as a signalling mediator between the luminal content and the underlying immune 
cells. Therefore the intestinal epithelial barrier plays a crucial role in the regulation of 
intestinal inflammation. As MKP-3 negatively regulates ERK activation, it plays a 
role in regulating cellular processes governed by ERK activation such as cellular 
proliferation. Therefore, as shown in the results of this study, MKP-3 regulates 
intestinal inflammation most likely by affecting IEC proliferation and migration, 
which are important processes in maintaining intestinal barrier integrity and 
preventing prolonged inflammation during intestinal mucosa injury. Nevertheless, 
further investigation on the IEC and the immune compartment separately will provide 
a better understanding of the role of MKP-3 in intestinal inflammation. 
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APPENDICES 
Supplementary Table 1. Colonic histological score sheet/criteria. 
Crypt Architecture 
0 = normal  
1 = irregular  
2 = moderate crypt loss (10-50%)  
3 = severe crypt loss (50-90%)  
4 = small/medium sized ulcers (<10 crypt widths)  
5 = large ulcers (>10 crypt widths) 
     
Crypt Abscesses 
0 = none 
1 = 1-5 
2 = 6-10 
3 = >10 
     
Tissue Damage 
0 = no damage 
1 = discrete lesions 
2 = mucosal erosions 
3 = extensive mucosal damage 
     
Goblet Cell Loss 
0 = normal 
<10% loss 
1 = 10-25% 
2 = 25-50% 
3 = >50% 
     
Inflammatory Cell Infiltration 
0 = occasional infiltration 
1 = increasing leukocytes in lamina propria 
2 = confluence of leukocytes extending to submucosa 
3 = transmural extension of inflammatory infiltrates 
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Supplementary Figure 1. MKP-3 expression was induced in CMT93 cells in 
response to (A) 2% DSS and (B) LPS (10 µg/ml) stimulation. CMT93 cells were 
stimulated with 2% DSS and 10 µg/ml and the expression of MKP-3 was examined at 




Supplementary Figure 2. Overexpression of KLF5 in CMT93 cell line confirms 
the specificity of the antibody used for Western blotting. CMT93 cells were 
transiently transfected with pcDNA empty vector and pcDNA harboring KLF5 cDNA 
sequence. Cells were subsequently harvested for protein analysis via Western blot.  
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Supplementary Figure 3. Basal expression level of several (A) inflammatory and 
(B) proliferation genes in the colon was comparable between wildtype and MKP-
3-/- mice, except for Cxcl1. The colon tissues of eight-week old untreated wildtype 
and MKP-3-/- mice were harvested and the expression level of several inflammatory 
and proliferation genes were measured via qPCR. Dot plots show individual values, 
means and standard deviations from two (male) and three (female) mice from each 
group. * P < 0.05 with unpaired t test. 
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Supplementary Figure 4. Expression of pro-inflammatory genes in BMDM upon 
LPS (100 ng/ml) stimulation. Bone marrow-derived macrophages from wildtype and 
MKP-3-/- mice were stimulated with 100 ng/ml LPS, followed by the measurement of 
the expression of pro-inflammatory genes via qPCR. 
 
